-
Je něco špatně v tomto záznamu ?
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry
K. Mądry, K. Lis, P. Fenaux, D. Bowen, A. Symeonidis, M. Mittelman, R. Stauder, J. Čermák, G. Sanz, E. Hellström-Lindberg, S. Langemeijer, L. Malcovati, U. Germing, MS. Holm, A. Guerci-Bresler, D. Culligan, L. Sanhes, I. Kotsianidis, C. van...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
36335984
DOI
10.1111/bjh.18542
Knihovny.cz E-zdroje
- MeSH
- akutní myeloidní leukemie * MeSH
- kardiovaskulární nemoci * MeSH
- lidé MeSH
- myelodysplastické syndromy * MeSH
- příčina smrti MeSH
- progrese nemoci MeSH
- registrace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
Department of Clinical Hematology Institute of Hematology and Blood Transfusion Praha Czech Republic
Department of Haematology Aarhus University Hospital Aarhus Denmark
Department of Haematology Aberdeen Royal Infirmary Aberdeen UK
Department of Hematology Radboud University Medical Center Nijmegen the Netherlands
Department of Internal Medicine 5 Innsbruck Medical University Innsbruck Austria
Department of Medicine Division of Hematology Karolinska Institutet Stockholm Sweden
Department of Medicine Division of Hematology University of Patras Medical School Patras Greece
Epidemiology and Cancer Statistics Group Department of Health Sciences University of York York UK
Service d'Hématologie Centre Hospitalier de Perpignan Perpignan France
Service d'Hématologie Centre Hospitalier Universtaire Brabois Vandoeuvre Nancy France
St James's Institute of Oncology Leeds Teaching Hospitals Leeds UK
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004410
- 003
- CZ-PrNML
- 005
- 20230425141347.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bjh.18542 $2 doi
- 035 __
- $a (PubMed)36335984
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Mądry, Krzysztof $u Department of Haematology, Transplantation and Internal Medicine, Warszawa Medical University, Warsaw, Poland $1 https://orcid.org/0000000280190371
- 245 10
- $a Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry / $c K. Mądry, K. Lis, P. Fenaux, D. Bowen, A. Symeonidis, M. Mittelman, R. Stauder, J. Čermák, G. Sanz, E. Hellström-Lindberg, S. Langemeijer, L. Malcovati, U. Germing, MS. Holm, A. Guerci-Bresler, D. Culligan, L. Sanhes, I. Kotsianidis, C. van Marrewijk, S. Crouch, T. de Witte, A. Smith, EUMDS Registry Participants
- 520 9_
- $a Information on causes of death (CoDs) and the impact of myelodysplastic syndromes (MDS) on survival in patients with lower-risk MDS (LR-MDS) is limited. A better understanding of the relationship between disease characteristics, clinical interventions and CoDs may improve outcomes of patients with LR-MDS. We prospectively collected data on patients with LR-MDS in the European MDS registry from 2008 to 2019. Clinical, laboratory and CoDs data were obtained. To examine MDS-specific survival, relative survival (RS) was estimated using national life tables. Of 2396 evaluated subjects, 900 died (median overall survival [OS]: 4.7 years; median follow-up: 3.5 years). The most common CoDs were acute myeloid leukaemia/MDS (20.1%), infection (17.8%) and cardiovascular disease (CVD; 9.8%). Patients with isolated del(5q) and with red cell transfusion needed during the disease course, had a higher risk of fatal CVD. The 5-year OS was 47.3% and the 5-year RS was 59.6%, indicating that most patients died due to their underlying MDS. Older patients (aged >80 years) and the lowest-risk patients were more likely to die from competing causes. This study shows that MDS and its related complications play crucial role in the outcome of patients with LR-MDS.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a příčina smrti $7 D002423
- 650 12
- $a myelodysplastické syndromy $7 D009190
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a registrace $7 D012042
- 650 12
- $a kardiovaskulární nemoci $7 D002318
- 650 12
- $a akutní myeloidní leukemie $7 D015470
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lis, Karol $u Department of Haematology, Transplantation and Internal Medicine, Warszawa Medical University, Warsaw, Poland
- 700 1_
- $a Fenaux, Pierre $u Service d'Hématologie, Hôpital Saint-Louis, Assistance Publique des Hôpitaux de Paris (AP-HP) and Université Paris 7, Paris, France $1 https://orcid.org/0000000204683553
- 700 1_
- $a Bowen, David $u St. James's Institute of Oncology, Leeds Teaching Hospitals, Leeds, UK
- 700 1_
- $a Symeonidis, Argiris $u Department of Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece $1 https://orcid.org/0000000236853473
- 700 1_
- $a Mittelman, Moshe $u Department of Medicine A, Tel Aviv Sourasky (Ichilov) Medical Center and Sackler Medical Faculty, Tel Aviv University, Tel Aviv, Israel $1 https://orcid.org/0000000176779119
- 700 1_
- $a Stauder, Reinhard $u Department of Internal Medicine V (Haematology and Oncology), Innsbruck Medical University, Innsbruck, Austria $1 https://orcid.org/0000000289939561
- 700 1_
- $a Čermák, Jaroslav $u Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Praha, Czech Republic
- 700 1_
- $a Sanz, Guillermo $u Department of Haematology, Hospital Universitario y Politécnico La Fe & Scientific Director IIS La Fe, Madrid, Spain
- 700 1_
- $a Hellström-Lindberg, Eva $u Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Langemeijer, Saskia $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands $1 https://orcid.org/0000000203660800
- 700 1_
- $a Malcovati, Luca $u Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
- 700 1_
- $a Germing, Ulrich $u Department of Haematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
- 700 1_
- $a Holm, Mette Skov $u Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
- 700 1_
- $a Guerci-Bresler, Agnes $u Service d'Hématologie, Centre Hospitalier Universtaire Brabois Vandoeuvre, Nancy, France
- 700 1_
- $a Culligan, Dominic $u Department of Haematology, Aberdeen Royal Infirmary, Aberdeen, UK
- 700 1_
- $a Sanhes, Laurence $u Service d'Hématologie, Centre Hospitalier de Perpignan, Perpignan, France
- 700 1_
- $a Kotsianidis, Ioannis $u Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece
- 700 1_
- $a van Marrewijk, Corine $u Department of Hematology, Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a Crouch, Simon $u Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK
- 700 1_
- $a de Witte, Theo $u Department of Tumor Immunology - Nijmegen Center for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, the Netherlands
- 700 1_
- $a Smith, Alex $u Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK $1 https://orcid.org/000000021111966X
- 710 2_
- $a EUMDS Registry Participants
- 773 0_
- $w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 200, č. 4 (2023), s. 451-461
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36335984 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141343 $b ABA008
- 999 __
- $a ok $b bmc $g 1924848 $s 1190619
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 200 $c 4 $d 451-461 $e 20221106 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
- LZP __
- $a Pubmed-20230418
